secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001104659-24-030726
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports positive Phase 1 data for APG777 with ~75-day half-life; FY2023 net loss $84M
--------------------------------------------------------------------------------

- APG777 Phase 1 interim data: half-life ~75 days, deep pSTAT6 and TARC suppression for ~3 months, well tolerated.
- Phase 2 in moderate-to-severe AD planned for 1H 2024; induction designed to exceed lebrikizumab exposures by 30-40%.
- Cash $395.5M at Dec 31, 2023; expected runway into Q4 2026.
- FY 2023 net loss $84.0M vs $39.8M from inception (Feb 2022) to Dec 2022; R&D expenses $68.4M.
- APG808 (anti-IL-4Rα) Phase 1 trial starting ahead of schedule; Phase 2 in COPD expected 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924030726/0001104659-24-030726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924030726/tm247826d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-030726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer